Clinical Trials

Multiple Myeloma

NCT05552976 2026-03-17

SUCCESSOR-2

525 enrolled

Multiple Myeloma, Recurrence

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

166 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05434689 2026-03-05

COMMANDER

80 enrolled

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

250 enrolled

Multiple Myeloma

NCT04933539 2026-02-27

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

14 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT01297764 2026-02-19

QUAD

17 enrolled

Multiple Myeloma

NCT05572515 2026-02-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT04113018 2026-02-03

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

39 enrolled 16 charts

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT04430894 2026-01-29

KRDI in Transplant-Eligible MM

50 enrolled 20 charts

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

118 enrolled

Multiple Myeloma

NCT04850599 2025-12-18

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

5 enrolled

Multiple Myeloma

NCT03290950 2025-12-15

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

75 enrolled

Multiple Myeloma

NCT03500445 2025-10-03

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

50 enrolled

Multiple Myeloma

NCT01559935 2025-09-08

CarBiRD

74 enrolled 12 charts

Multiple Myeloma

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

1,087 enrolled

Multiple Myeloma

NCT03314636 2025-08-08

CONPET

53 enrolled

Neoplasms, Plasma Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04458831 2025-06-27

IONA-MM

Active not recruiting

583 enrolled

Multiple Myeloma

NCT01816971 2025-06-10

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

76 enrolled 12 charts

Phase 1 Active not recruiting

Multiple Myeloma

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

83 enrolled

Multiple Myeloma, Recurrence

NCT03556332 2025-04-29

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

41 enrolled

Multiple Myeloma

NCT04263480 2025-04-04

CZAR-1